Sanofi annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi Stock-Based Compensation Growth & History (SAN)
Sanofi's stock-based compensation was €313.0M for fiscal 2025.
View full Sanofi company overviewSanofi annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €313.0M | €35.0M | +12.59% |
| 2024 | 2024-12-31 | €278.0M | €18.0M | +6.92% |
| 2023 | 2023-12-31 | €260.0M | €26.0M | +11.11% |
| 2022 | 2022-12-31 | €234.0M | −€10.0M | −4.10% |
| 2021 | 2021-12-31 | €244.0M | −€30.0M | −10.95% |
| 2020 | 2020-12-31 | €274.0M | €22.0M | +8.73% |
| 2019 | 2019-12-31 | €252.0M | −€32.0M | −11.27% |
| 2018 | 2018-12-31 | €284.0M | €26.0M | +10.08% |
| 2017 | 2017-12-31 | €258.0M | €8.0M | +3.20% |
| 2016 | 2016-12-31 | €250.0M | €44.0M | +21.36% |
| 2015 | 2015-12-31 | €206.0M | — | — |
Sanofi stock-based compensation trends
Over the last five fiscal years, Sanofi's stock-based compensation increased from €274.0M to €313.0M, a change of €39.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗